Cencora's specialty pivot lifts margins but integration costs and customer churn keep the thesis in wait mode.

What happened

Cencora is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, with acquisitions of OneOncology and Retina Consultants of America driving Q2 gross margin expansion to 4.31% and management raising FY2026 adjusted EPS guidance to $17.70–$17.90. However, the DeepValue report highlights that integration costs remain elevated at $164 million quarterly, DS&A deleveraged 40 basis points to 2.52% of revenue, and share repurchases were zero in the first half of FY2026 despite a $2 billion authorization. Customer losses in oncology and grocery segments, along with mail-order mix shifts from biosimilar conversions, add headwinds that must be offset by services growth. The raised guidance depends on OneOncology's contribution persisting while list-price reductions create a $2 billion quarterly revenue drag. Until Q3 FY2026 data shows integration costs declining and buybacks accelerating, the stock's 21.9x P/E offers limited margin of safety.

Implication

Over the next six months, focus on whether OneOncology integration costs decline from $164 million per quarter and DS&A% drops below 2.45%, while repurchases show run-rate toward $1 billion by year-end. If both materialize, the stock could re-rate toward $310; if not, customer mix issues and leverage risk point to $250.

Thesis delta

The narrative has shifted from pure distribution to specialty infrastructure, but execution risks remain. The positive guidance raise and margin lift are real, but they hinge on integration cost control and buyback resumption, which have not yet been proven. Until those proofs emerge, the thesis remains on hold.